Module 4 — Nonclinical Study Reports (Index & Stubs) — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The Module 4 index and study-report stubs — the map of the animal pharmacology, PK, and toxicology reports.
Why it exists. Module 4 holds the full nonclinical study reports that justify human dosing. This index shows which studies exist and how they map to the CTD structure (§4.2.1-4.2.3).
How it is produced here. No real animal studies were run for this portfolio, so this is deep-knowledge mock: the study designs, endpoints, and conclusions are realistic domain content standing in for real laboratory data.
Format & governing standard. ICH M4S; CTD §4.2; SEND (planned)
Module 4 — Nonclinical Study Reports (Index & Stubs) — GLPI-103
| Field | Value |
|---|---|
| Document ID | M4 |
| Version | 1.0 |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Standard | ICH M4S; CTD §4.2; SEND (planned) |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]No nonclinical wet-lab data are generated. This is the §4.2 index; full real-form study reports are in M4-2.1 (pharmacology), M4-2.2 (PK/ADME), and M4-2.3 (toxicology, incl. the pivotal 26-week rat study in full). Interpretive content in M2.4; tabulated summaries in M2.6. Nonclinical data would be standardized to SEND.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Nonclinical | Initial M4 index/stubs |
4.2.1 Pharmacology
| Report | Type | Key result (illustrative) |
|---|---|---|
| PD-IVT-01 | In-vitro potency/selectivity | GLP-1R EC₅₀ 14 pM; APJ EC₅₀ 48 pM; inactive at GIP/glucagon R |
| PD-PRIM-01 | Primary PD (db/db, DIO in vivo) | HbA1c −1.8% vs −1.1% comparator; weight −18%; +58% clamp GIR |
| PD-SEC-01 | Secondary PD / off-target panel | No significant off-target hits |
| PD-SAFP-01 | Safety pharmacology (S7A/S7B) | hERG IC₅₀ >30 µM (>1000×); no QT/CNS/respiratory liability |
4.2.2 Pharmacokinetics (S3A)
| Report | Type | Key result |
|---|---|---|
| PK-ADME-01 | ADME (rat/monkey) | Dose-proportional; long t½; proteolytic catabolism |
| PK-IMM-01 | Immunogenicity | Low-titer, non-neutralizing ADA |
4.2.3 Toxicology (S-series)
| Report | Type | Key result |
|---|---|---|
| TOX-RD-01/02 | Repeat-dose (26-wk rat / 39-wk monkey) | Reversible exaggerated-pharmacology; NOAEL ≈25× (rat)/20× (monkey) |
| TOX-GEN-01 | Genotoxicity battery (S2) | Negative |
| TOX-CARC-01 | Carcinogenicity (S1) | Rodent-specific thyroid C-cell finding; human-relevance assessed (QA-003 ISS-012) |
| TOX-REPRO-01 | Reproductive/developmental (S5) | Maternal-toxicity-limited; no unique teratogenicity |
Full study reports (with GLP statements and SEND datasets) would populate each stub in an actual submission. Conclusions are integrated in M2.4 §5.
Comments (0)
No comments yet. Be the first to say something!